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The approaches in prevention and therapy of acute coronary syndrome (ACS) are 
different ways of conservative and invasive procedures which have contributed to 
reduction of mortality of ischemic heart disease (IHD) by 20 %, approximately, in many 
parts of the world in the recent 20 years. Beta blockers (BBs) have given significant 
contribution to prevention and therapy of ACS, especially their use in ACS and in the first 
years of secondary prevention of IHD. The aim of the study was the estimation of patients 
with ACS in Serbia in the period 2000 – 2005, as well as the evaluation of BB use in ACS 
and resolving dilemma concerning their prescription. 
The data about patients were obtained from the National Register for ACS in Serbia. 
Lately, there has been a marked increase in the number of coronary units (CU) and 
patients with ACS. In admission diagnoses, there was the largest number of patients with 
AMI or 69,7%, with the highest total mortality of 11,7 %. In addition, higher rates of male 
patients than female ones, as well as an increase of male patients in the age group of 50-
59 years, and an increase of female patients in the age group of  70-79 years were 
reported. It is interesting that the rate of female patients is higher than presented in 
literature. It is noted that the rate of AMI with ST segment elevation (STEMI) is more 
frequent than AMI without ST elevation (NSTEMI). STEMI is more frequent in younger 
patients and male ones. Case-fatality of STEMI patients is significantly higher compared 
with NSTEMI patients (p<0,000). The percentage of  patients with ACS treated with BB is 
still low and it has not been changed significantly in recent years. Acta Medica Medianae 
2008;47(3):28-34. 
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Introduction 
 
The term ACS is an expression used in recent 
years for a diagnosis of acute coronary disease, 
occurring within first hours or in the first days of 
the beggining of symptoms of the disease. Unstable 
angina pectoris, STEMI, NSTEMI and sudden death 
stand for the acute forms of coronary disease. 
In order to select an appropriate therapeu-
tic approach, there is a need for precise diagnosis 
and risk evaluation of future cardiac events, so 
t h a t  e v a l u a t i o n  s h o u l d  b e  d o n e  e a r l y ,  b a s e d  o n  
available clinical electrocardiographic and sensitive 
and specific biomarkers (17). New cardiospecific 
markers, troponin I and troponin T enabled better 
diagnosis of myocardial necrosis, and the use of 
thrombolytic therapy (TT) and percutaneous 
coronary intervention (PCI) as a standard therapy 
in STEMI. The use of antithrombotic drugs and PCI 
in NSTEMI and in unstable AP have helped to 
define the importance of ACD, first of all because 
of appro-priate therapy whose efficiency is 
mainly determi-ned by fast drug application (1). 
Early BB application in AMI has given objective 
evidences of the favourable effect, because it 
reduces intensity of chest pain, reduces ST segment 
elevation on ECG in transmural infarction and 
reduces the concentration of creatine kinase. The 
use of BBs reduces the heart volume, arterial 
blood pressure and retards pulse, the result of 
which is the reduction of oxygen consumption 
and lactic creation (2). 
It is considered that continuation of BB 
therapy after acute phase is important in 
reducing possible extention of infarctional zone. 
The prophylactic use of BBs after AMI has an 
excellent effect, first of all in patients with uncompli-
cated infarction. Those patients with heart 
insuffiency (HI), ischemia or serious arrhythmia 
must have individual therapy depending on 
complete clinical status. It is considered that 
50% of patients after AMI can be treated with 
BBs, following the indications. 
All BBs are efficient in treating AP, although 
some groups of BBs have some specific characte-
ristics, which are important for some groups of 
patients with AP (3). Acta Medica Medianae 2008,Vol.47                       Use of beta blockers in acute coronary syndrom... 
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Convincing evidences of reduction on 
mortality achieved by BBs in patients with AMI in 
postinfa-rction monitoring at the beggining of the 
'80s, have brought to presumption that this way 
of treatment has to improve the result in angina 
on exertion and in unstable angina. Unfortunately, 
there have not been done yet good studies which 
could support this presumption. 
Exhaustive controlled clinical studies affirm 
beta-blockers as drugs that reduce mortality in 
secondary prevention of ischemic heart disease 
(7,8). 
The analysis of 14-year follow-up showed 
that the therapy with aspirin, BB and coronary 
revascularisation is successful when it comes to 
intermediary goals, i.e. infarction relapse, anginal 
attacks and repeated revascularisation, but the 
cumulative effect on mortality is not clear (12). 
 
Aims 
 
The aim of the research was the estimation 
of patients with ACS in Serbia in the period from 
2000 to 2005, and also the estimation of BB use 
in ACS and resolving dilemma related to their 
prescription. 
 
Material and methods 
 
The method of analysis means the estimation 
of patients with ACS in CU and UIC in Serbia in 
the period from 2000 to 2005. 
The research summarizes the results of six- 
year-long study which are presented in tables 
and graphs. Descriptive and analytical methods 
were used in the research. The groups of 
examinees were divided according to sex, age 
and structural forms of ACS. 
The results were obtained during one year 
based on data processing of the number of 
patients with ACS in Serbia collected for the first 
time in 2003 by the team of ACS experts in the 
Ministry of Health. The data from National 
Register for ACS in Serbia were compared to the 
data for ACS from European countries-Euro Heart 
Survey ACS II (EHS ACS II) from 2004, which 
included 6,356 patients from 32 countries. Unique 
epidemic data were collected by means of 
coronary reports containing minimal necessary 
data about all patients treated in CU and UIC in 
Serbia. 
The unpublished data from Public Health 
Institute „Dr Milan Jovanovic Batut“ in Belgrade 
were used for the estimation of BBs in ACS in 
Serbia and they were compared to the data from 
EHS ACS II from 2004. The data about 
estimation of BB consumption in the world were 
taken from the site www.legemiddelforbruket.no. 
The analysis enabled resolving the existing 
therapeutic dilemma and more exact estimation 
of succesful treatment. The analysis was a help 
to doctors to decide about therapy procedure 
(Evidence- based medicine), shape science-based 
instructions for clinical practice (Evidence- based 
practice) and gives contribution for further 
research. 
Results 
 
The patients of both sexes and different 
ages with ACS in CU and UIC care in Serbia were 
involved in the six-years-long period from 2000 
to 2005.  
We noticed that the data about the number 
of patients with ACS in 2000 and 2001 in Serbia 
were missing or incomplete (Tables 1,2). 
 
Table 1. Data of ACS in Serbia for the year 
2000 
 
unchanged number of beds for 15 years 
(the number of patients has increased in 
the City of Belgrade by 50 %) 
inadequate access, 
inadequate keeping of medical 
documentation 
 
Table 2. Data of ACS in Serbia for 2001 
 
28 CU and UIC (incomplete data) 
mortality from AMI: 18 % 
 
According to incomplete data for November 
2002 and based on the results from 48 CU and 
UIC in Serbia, 786 patients were treated, average 
age 63±1 years (20-87 years of age). According 
to sex it was registered that 59 % were men with 
ACS, 61±12 (70% - 62±12, EHS ACSII) years 
and 41% were women, 66±10 (30% 70±12, EHS 
ACSII) years. TT was used in a significantly low 
percentage of patients i.e. in 15.1% of patients 
(Table 3). 
 
Table 3. Data of ACS in Serbia for 
November, 2002 
 
48 CU 
786 patients, 20-87 years of age (63±11) 
M :      W :  
59 %, 61±12, Serbia      41 %, 66±10, 
Serbia 
70 %, 62±12, EHS ACS II   30 %, 70±12, 
EHS ACS II 
with TT:     15,1  % 
patients 
 
Analyzing the results obtained from 50 CUs 
and UICs in 2003 in Serbia, we noted that 12.739 
of patients were treated, of which 8.883 patients 
had AMI diagnosis. Further analysis indicated 
that according to sex, 62.7% of patients were 
men and 37.3% were women. The average age 
of men was 61.06±11.7 years, and of women 
65.76±10.46 years. The youngest patient was 19 
years old and the oldest was 93 years old. During 
hospital admissions, ST segment changes on ECG 
were observed in patients with STEMI and 
NSTEMI. In 6.716 patients or 75.6%, ST segment 
elevation was registered, while in 2.167 patients 
or 24.4%, ST segment elevation was not 
registered. ST segment elevation was statistically 
significantly more frequent in younger patients Use of beta blockers in acute coronary syndrom...                  Vesna V Radović 
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than in older ones. Women were more numerous 
in NSTEMI group than in STEMI group. TT was 
given to 1,965 patients or 29,26% of 6,716 
patients in total. 
It should be noted that the number of 
patients treated with TT in 2003 was significantly 
lower in relation to the European recommendations. 
In the group of patients treated with TT, 
case fatality was 7,5%, i.e. 147 patients of 1,965 
deceased. TT was not applied in 4,751 cases. In 
this group of patients, case fatality was 15,3%, 
i.e. 726 patients deceased. The difference in the 
prognosis of patients, with and without applied 
TT, was statistically very high (P<0,000). The 
total mortality for STEMI was 13,0%, and for 
NSTEMI 7,6% (Table 4). 
 
Table 4. Data of ACS in Serbia for 2003 
 
males  62,7 %, 61,06±11,7  50 KJ (12739 
patients)  females  37,3 %, 65,76±10,46 
STEMI 
6 716 patients, 75,6 % 
35% females,  
total mortality 13%  AIM (8883 
patients) 
NSTEMI 
2 167 patients, 24,4 % 
38% females,  
total mortality 7,6% 
with TT:        1 965 patients, 29,26 % 
case fatality: 147 patients, 7,5 % 
without TT:   4 751 patients 
case fatality: 726 patients, 15,3 % 
 
In 2003, in the admission diagnoses, the 
most of the patients were diagnosed with AMI 
(69,7%). In this group of patients, the highest 
total mortality of 11,7%  was reported (Table 5). 
 
Table 5. Structure in the form of ACS and total 
mortality in the course of 2003 
 
Year 2003: 
AMI: 8 883 patients, 69,7 % 
unstable AP: 3 856 patients, 30,27 % 
total mortality from AMI: 11,7 %, 
hospital mortality of AMI: 8,9 %, 
total mortality of unstable AP: 1,6 % 
 
In 2004, in CU and UIC in Serbia (CU of the 
Institute of Cardiovascular Diseases Sremska 
Kamenica, CU of the Health Care Centre in 
Leskovac and the Health Care Centre in Vranje 
were not included), 19.859 patients were treated, 
of which 12.351 or 62.2% had ACS diagnosis. 
Also, an increase in the number of patients 
with ACS for previous year was reported. 
According to sex, 63,1% were men and 36,9 % 
were women. The average age of men was 
61,53±11,32 years, and of women 66,05±10,62 
years. The statistical data related to sexes and 
the average age were not significantly different 
compared to data from 2003. From the total number 
of patients with AMI, of which 8.360 were regi-
stered in 2004, there were 6,393 patients with 
STEMI or 76,5%, and 1,967 patients with 
NSTEMI or 23,5%. The number of patients with 
STEMI and NSTEMI did not differ much statisti-
cally in regard to 2003. It is confirmed that ST 
segment elevation was statistically significantly 
more frequent in younger patients than in older 
ones. Of 6,393 STEMI patients, 1,972 patients or 
30,8% were treated with TT. Case- fatality was 
7,6%, i.e. 150 patients of this group died. 4,421 
patients or 69,2% were not treated with TT. In 
this group, case-fatality was 14,5%, i.e. 642 
patients died. The difference in the prognosis of 
patients treated or not with TT in 2004 was 
statistically very significant. The number of patients 
treated with TT in 2004 was significantly smaller 
in regard to the European recommendations. It was 
noted that, thanks to TT and better diagnostics, 
the mortality of patients with AMI was signifi-
cantly reduced during the last 3 years in Serbia. 
Case fatality of patients with AMI and ST 
elevation and patients treated with TT statistically 
was significantly lower (p<0,000) compared to the 
group which was not treated with TT (Table 6).   
 
Table 6. Data of ACS in Serbia for 2004 
 
50 CU               19 859 patients               
ACS 12 351 patients, 62,2 % 
M :      W :  
63,1 %, 61,53±11  36,9 %, 66,05±10,62 
AMI: 8 360 patients 
STEMI:     NSTEMI: 
 6 393 patients, 76,5 %  1 967 patients, 23,5 % 
 with TT:        1 972 patients, 30,8 % 
 case fatality:  150 patients, 7,6 % 
 without TT:   4 421 patients, 69,2 % 
 case fatality:  642 patients, 14,5 % 
 
We registered that, according to sex, the 
results for 2005 were similar to the data of the 
year before (Table 7).     
 
Table 7. Data on ACS in Serbia for December 1 -31, 
2005 
 
51 CU 
12 739 patients, 
age adjusted rate 61 ± 11; 19-93 years of age 
M:     60,9  %,  61±11 
W:     39,1  %,  65±8 
with TT: 36,4 % 
 
The most numerous age group of patients 
with ACS was from 50 to 79 years in 2005 
(Graph 1) 
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Graph 1. Patients of ACS presented by age groups in 
the course of 2005 
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Table 8. Registration year, number of patients with ACS 
and therapy in the period from 2002 to 2005 
 
 Patients  (%) 
Year 2002  2003  2004  2005 
Number of 
patients  4 202  12739  12 351  12 598 
Aspirine 86,0  88,1  89,9 
EHS ACS II  97  85,8 
Heparine 77,2  77,1  83,4         
EHS ACS II  94  82,1 
Nitroglycerine 72,1 77,3 81,8  
EHS ACS II  75  73,5 
Beta blockers  52,8  52,3  56,1  
EHS ACS II  83  56,5 
ACE 
inhibitors  51,3 51,5 55,7  
EHS ACS II  71  53,1 
Diuretics 9,1  29,9  33,6  33,6 
*Source: unpublished data of the Public Health Institute 
Serbia "Dr Milan Jovanovic Batut", in October, 2007 
In the period from 2002 to 2005, we 
registered that the percentage of patients with 
ACS treated with BB was still low and it has not   
changed significantly in recent years (Table 8). 
The following data are from Norwegian site 
which has regular and very detailed data processing 
about drug consumption and it is often an 
indicator how certain drug is ranked in Europe. 
According to the sales in million of NOK, BB 
were ranked 3
rd (CV system) in the period from 
2002 to 2006 (Table 9).  
Also, the continual increase of BB consu-
mption according to DDD can be noted in the 
period from 1990 to 2006 (Graph 2). In the 
following tables you can see the 10 most sold 
POMs (prescription only medicine) in 2006. 
According to the sales in million of NOK, 
metoprolol is ranked 7
th, and according to DDD it 
is ranked 6
th (Table 11,12). 
 
 
Table 9. Sales per ATC 3rd level for ATC group C - Cardiovascular system 
 
      mill NOK (AUP) 
ATC  ATC  level  name  2002 2003 2004  2005  2006 
                    
C01A  Cardiac  glycosides  6,9 6,6 7,6  7,2  8,6 
C01B  Antiarrhythmics, class I and III  24,5  22,7  18,7  19,8  20,1 
C01C  Cardiac stimulants excl. cardiac glycosides  12,1  13,5  15,4  18,4  20,0 
C01D  Vasodilators used in cardiac diseases  102,6  85,6  81,5  73,2  65,5 
C01E  Other cardiac preparations  1,3  1,2  1,2  1,2  1,0 
C02A  Antiadrenergic agents, centrally acting  8,5  9,4  9,8  10,1  10,7 
C02C  Antiadrenergic agents, peripherally acting  87,5  76,5  45,3  38,6  29,6 
C02D  Arteriolar smooth muscle, agents acting on  0,2  0,3  0,3  0,3  0,3 
C02K  Other antihypertensives     4,9  15,0  22,1  21,9 
C03A  Low-ceiling diuretics, thiazides  5,6  6,8  11,3  15,9  19,9 
C03C  High-ceiling  diuretics  51,8 51,9 60,0  59,7  56,2 
C03D  Potassium-sparing  agents  8,7 8,9 8,9  9,3  10,4 
C03E 
Diuretics and potassium-sparing agents in 
combination 
7,8 7,8 8,5  7,3  7,3 
C04A  Peripheral  vasodilators  6,0 5,2 4,7  3,7  2,3 
C07A Beta  blocking  agents  257,3 255,7 268,5  259,2  258,5 
C07B Beta  blocking  agents  and thiazides     0,9  2,7  4,4  4,6 
C08C 
Selective calcium channel blockers with mainly 
vascular effect 
320,0 289,3 243,5  149,0  142,2 
C08D 
Selective calcium channel blockers with direct cardiac 
effects 
47,8 42,6 39,8  35,8  31,9 
C09A  ACE-inhibitors,  plain  206,9 177,3 135,9  77,3  80,2 
C09B  ACE-inhibitors,  combinations  78,5 67,8 57,1  35,2  29,8 
C09C  Angiotensin II antagonists, plain  248,5  267,3  293,5  324,5  330,0 
C09D  Angiotensin II antagonists, combinations  215,4  247,7  301,1  364,6  390,1 
C10A  Lipid modifying agents, plain  1105,1  1091,3  970,4  807,4  646,5 
C10B  Lipid modifying agents, combinations              0,02 
 Use of beta blockers in acute coronary syndrom...                  Vesna V Radović 
 
32
 
Graph 2. Sales of antihypertensives (C02), diuretics (C03), beta blocking agents (C07) calcium channel blockers 
(C08) and ACE-inhibitors + angiotensin II antagonists (C09) 1990 - 2006 
 
Table 10. Sales of 10 most sold POMs ranked according to the sales in million of AUK in 2006 
 
ATC kode 
ATC code 
Virkestoff 
Active ingredient 
Bruksområde 
Indication 
Million DDD 
Million DDD 
Million kr (AUP) 
Million NOK (AUP) 
L04AA11 Etanercept  Leddgikt  m.m.  1  434 
C10AA05 Atorvastatin  Kolesterolsenkende  86  377 
R03AK06 Salmeterol  og  flutikason  Astma/KOLS  21  350 
A02BC05 Esomeprazol  Spiserørsbetennelse  m.m. 28  349 
L04AA12 Infliximab  Leddgikt  m.m.  1  260 
N05AH03 Olanzapin  Psykiske  lidelser  5  208 
C07AB02 Metoprolol  Hjerte/kar  sykdom  40  199 
R03AK07 Formeterol  og  budesonid  Astma/KOLS  11  194 
C10AA01 Simvastatin  Kolesterolsenkende  144  180 
C09DA01  Losartan og hydroklortiazid  Hjerte/kar sykdom  21  168 
 
Table 11. Sales of the 10 most sold POMs ranked according to the sales in million of DDDs (Includes only drugs with DDDs) in 2006 
 
ATC kode 
ATC code 
Virkestoff 
Active ingredient 
Bruksområde 
Indication 
Million DDD 
Million DDD 
Million kr (AUP) 
Million NOK (AUP) 
C10AA01 Simvastatin  Kolesterolsenkende  144  180 
B01AC06 Acetylsalisylsyre  Blodpropp  forebyggende  108  110 
C10AA05 Atorvastatin  Kolesterolsenkende  86  377 
N05CF01 Zopiklon  Sovemiddel  52  99 
C08CA01 Amlodipin  Hjerte/kar  sykdom  51  60 
C07AB02 Metoprolol  Hjerte/kar  sykdom  40  199 
C09AA05 Ramipril  Hjerte/kar  sykdom  40  41 
C03CA01 Furosemid  Hjerte/kar  sykdom  37  34 
H03AA01 Levothyroksinnatrium  Thyroksintilskudd  36  50 
R06AE07 Cetirizin  Pollenallergi  36  43 
 
Discussion 
 
In our country, as in many countries in 
transition, an increase of mortality and incidence 
in ACS has been reported. The mortality in AMI is 
about 30%, of which more than half of all deaths 
occur before a sick person arrives to hospital. 
Although survival after hospitalization has improved 
in the last 20 years, additional 5-10% of survived 
patients die in the first year after infarction (9). 
There is a continual risk of increased mortality 
and new infarctions in recovered patients (10). 
There is no country in which data collection 
about the incidence of CV diseases is regular. In Acta Medica Medianae 2008,Vol.47                       Use of beta blockers in acute coronary syndrom... 
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observing morbidity, MONICA study data were 
mainly used. The City of Novi Sad in Serbia was 
included in the MONICA study. Heart diseases 
represent a leading cause of premature death in 
most developed countries of the world as well 
(11). On the scale of the countries ranked 
according to the rates, Serbia is placed in the 
upper third for female population and a little 
above the middle for male population. In Serbia, 
without Kosovo and Metohia, the rate of mortality 
in 1996 was 800 for men and 600 for women, 
from 45 to 70 years of age, which puts our 
country on the top of the ranked countries (13). 
The aim of this study was to emphasize the 
importance of regular collection of epidemic data 
about the number of patients with ACS in Serbia, 
during one year and also, to emphasize the 
importance of BB use in ACS, particularly in 
secondary prevention of IHD, which was confirmed 
by numerous clinical trials. The study confirmed 
the facts that, besides strong arguments and 
numerous recommendations, BBs have not been 
accepted enough as an integral part of treatment 
of ACS in Serbia. Consequently, there have been 
many deceased despite favorable pharmacoe-
conomic condition. 
On the other hand, in the world, BBs represent 
a standard treatment for angina on exertion, 
mixed angina on exertion and at rest, as well as 
unstable AP. BB reduces case-fatality in acute 
phase of infarction and in postinfarction phase, 
which contributed to prolongation of life in CV 
patients. The data about monitoring of posti-
nfarction phase are particularly convincing (14). 
The analysis of medical documentation of 
over 200.000 patients shows that, even in states 
which are often considered CI for BBs, such as 
heart failure, pulmonary diseases, patients 
without transmural infarction and old-aged 
population, have all benefits of BB (15). 
According to the results of the Euro Heart 
Survey Acute Coronary Syndrome II (EHS II), 
BBs are being applied in 83% of patients, and 
according to the multicontinental study GRACE, in 
79% of patients (4,5). In RIKS-HIA, the Swedish 
register with 26.000 subjects suffering from AIM 
with ST elevation, it has been stated that BBs     
applied from 1999 to 2004 in 84,7 % of patients 
treated with in-hospital thrombolysis, and in 88,9% 
of patients treated with prehospital thrombolysis 
(6). In our conditions, BBs have been applied 
considerably less frequently; according to the 
data from 2002 in 52,8% of patients, in 2003 in 
52,3%, in 2004 in 56,1%, and in 2005 in 56,5% of 
patients with ACS. It would be interesting to mention 
that every year the use of BB in the treatment of 
patients with ACS considerably increases, which 
was especially noticeable in 2004 and 2005, 
though it is still less present in comparison with 
the data of the European regions. 
The working group ACC/AHA considers that 
early i.v. beta-blockade is induced for patients 
without CI. It is interesting that retrospective 
analysis of National Infarction Register in USA 
which shows that intracranial hemorrhage with 
immediately applied i.v. beta-blockade has been 
reduced by 31%. Intracranial hemorrhage is the 
major threat for plasminogen activation. 
In the postinfarction phase, the use of BB 
reduces case-fatality by 35-40% in different 
kinds of patients (16). Without going into details 
about advantages of certain groups of drugs’ 
application or invasive procedure, the place of 
BBs in therapy protocols, either for STEMI or 
NSTEMI, is undoubtedly very important (18). The 
first studies showed that in the prethrombolytic 
era, as well as the combined use of thrombolysis 
and BBs in TIMI II study in patients with 
complete infarction. The recent CP study shows 
that intense BB therapy is of vital importance for 
the most of NSTEMI patients (19). 
BBs reduce morbidity and mortality immedi-
ately after infarction, but also weeks, months and 
years after infarction (20,21). According to the 
recommendations of the European Society of 
Cardiology, in the treatment of patients with 
NSTEMI and STEMI, as primarily anti-stress 
medications, BB find their place in infarction 
therapy, if they are not contraindicated (22). 
BBs are the most efficient antianginal drugs 
for reduction of ischemia in ambulatory patients. 
They reduce the needs of the myocardium for 
oxygen, reducing heart frequency, contractility and 
systolic blood pressure during exertion. They are 
highly efficient as a monotherapy for AP and are 
the drugs of choice for angina after infarction (2). It 
is considered that BBs are effective alone or with 
other drugs in 70-80% of patients with classic angina. 
Timely diagnosis and treatment with modern 
methods (like a PCI superior method) have 
significantly improved the prognosis of patients 
with ACS (23,24). 
Therefore, the application of BBs in ACS 
should be considered seriously by changing 
prescription habits and overcoming groundless 
fear in some of the doctors. Unmistakably, the 
benefit of prescribing overcomes possible risks. 
 
Conclusion 
 
The results show that Serbia is at the top of 
the list of countries with average yearly increase 
of morbidity and mortality of CV disease. 
In Serbia, the drug choice does not significantly 
influence the prescription and consumption of BB, 
which should be proportional to their clinical 
significance and therapy possibilities. It is interesting 
that this is all happening  when great controlled 
clinical trials confirm BBs as medicines which 
reduce mortality in primary and secondary 
prevention of IHD and congestive heart failure. 
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PRIMENA BETA BLOKATORA U AKUTNOM KORONARNOM SINDROMU 
U SRBIJI U PERIODU OD 2000. DO 2005. GODINE 
 
Vesna V Radović 
 
Pristupi u prevenciji i terapiji akutnog koronarnog sindroma (AKS) su razni modaliteti 
konzervativnih i invazivnih procedura, koji su doprineli da se poslednjih 20 godina, u 
mnogim delovima sveta, mortalitet od ishemijske bolesti srca (IBS) smanjio za oko 20%. 
Značajan doprinos tome dali su beta blokatori (BB), naročito njihova primena u AKS i 
prvim godinama sekundarne prevencije IBS. Cilj rada bila je procena bolesnika sa AKS u 
Srbiji u periodu od 2000. do 2005. godine, kao i procena primene BB u AKS i otklanjanje 
nedoumica vezanih za njihovo propisivanje.  
Podaci o obolelima dobijeni su iz Nacionalnog registra za AKS (REAKS) u Srbiji. U 
proteklom periodu zapažen je porast broja koronarnih jedinica (KJ) i porast obolelih od 
AKS. U prijemnim dijagnozama bilo je najviše bolesnika sa AIM ili 69,7%, gde je zabeležen 
i najveći ukupan mortalitet od 11,7%. Uočena je veća zastupljenost obolelih muškaraca u 
odnosu na obolele žene i to porast obolelih muškaraca u starosnoj grupi od 50 do 59 
godina i porast obolelih žena u starosnoj grupi od 70 do 79 godina. Interesantna je velika 
zastupljenost ženskog pola, veća nego što se navodi u literaturi. Zapaženo je da se 
registruje značajno češća zastupljenost AIM sa elevacijom ST segmenta (STEMI), u odnosu 
na AIM bez ST elevacije (NSTEMI). STEMI je češći kod mlađih bolesnika i kod muškaraca. 
Letalitet bolesnika sa STEMI je značajno veći u odnosu na bolesnike NSTEMI (P<0,000). 
Procenat bolesnika sa AKS koji je primao BB i dalje je mali i nije se značajno menjao 
poslednjih godina. Acta Medica Medianae 2008;47(3):28-34. 
 
Ključne reči: beta blokatori (BB), akutni koronarni sindrom (AKS), sekundarna 
prevencija ishemijske bolesti srca (IBS) 